Trial
NCT06180863
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Yale University
Collaborators
Bristol-Myers Squibb; National Cancer Institute (NCI)
Condition
Acute Myeloid Leukemia
Intervention
oral azacitidine (CC-486)
Why stopped
Lack of funding.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-26